Study Finds COVID-19 Virus Particles in Retinas of Infected, Deceased Patients
Previous research has shown that COVID-19 can impact ocular health.
Related Articles
Benefit of Aspirin Could Depend on Lipoprotein(a) Levels, Study Finds
An analysis of NHANES found aspirin’s benefits in primary prevention may hinge on lipoprotein(a) (Lp(a)) levels, halving ASCVD mortality risk with Lp(a) ≥50 mg/dL.
FDA Approves High-Concentrate, Citrate-Free Formulation of Biosimilar Adalimumab-adbm
The current approval is based on the VOLTAIRE-HCLF clinical trial, which examined the bioavailability of high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations of adalimumab-adbm.
Colchicine Treatment Significantly Improves COVID-19 Outcomes
Findings indicated treatment with colchicine resulted in a significant reduction in mortality rate compared with placebo or standard care.
Recognizing Stigma’s Impact on Care for Alcohol-Related Liver Disease
In the first segment of this HCPLive special report, experts discuss the stigma surrounding alcohol use disorder and alcohol-associated liver disease.
Discussing Risankizumb, Differences in IL-23 Inhibitor Epitopes with Christopher Bunick, MD, PhD
This interview with Bunick featured a discussion of his team’s recent data comparing anti-IL-23 biologics, epitopes, and comparisons with risankizumab.
Endocrinology Month in Review: April 2024
The HCPLive Endocrinology month in review for April 2024 spotlights SURMOUNT-OSA, STEP HFpEF DM, new ACP guidelines for T2D, and more!
Study Design, and BCVA and Durability Outcomes of VABYSMO in DME: YOSEMITE & RHINE
Chapter 5: VABYSMO (faricimab-svoa) is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet)…
Discussing Risankizumb, Differences in IL-23 Inhibitor Epitopes with Christopher Bunick, MD, PhD
This interview with Bunick featured a discussion of his team’s recent data comparing anti-IL-23 biologics, epitopes, and comparisons with risankizumab.
Lebrikizumab for Atopic Dermatitis Resubmitted for FDA Approval After Previous Rejection
The decision by Eli Lilly to resubmit lebrikizumab to the FDA for adults and adolescents with eczema is expected to receive a response in the…
Nurse-Led Gout Care Linked to Better Medication Adherence
Among the nurse-led cohort, 83% of patients with gout achieved target p-urate levels and 98% continued treatment with urate lowering therapy.